Alder BioPharmaceuticals (NASDAQ:ALDR) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 4 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys.
Other Equity analysts have also commented on the company shares. Brean Capital initiates coverage on Alder BioPharmaceuticals (NASDAQ:ALDR). The shares have now been rated Buy by the stock experts at the ratings house. Brean Capital announces the current price target of $45 per share on Alder BioPharmaceuticals . The rating by the firm was issued on April 20, 2016.
Alder BioPharmaceuticals (NASDAQ:ALDR): 3 Analyst have given the stock of Alder BioPharmaceuticals (NASDAQ:ALDR) a near short term price target of $49. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $10.58. The higher price target estimate is at $61 while the lower price estimates are fixed at $41.
Alder BioPharmaceuticals (NASDAQ:ALDR) witnessed a decline in the market cap on Tuesday as its shares dropped 6.78% or 1.83 points. After the session commenced at $26.95, the stock reached the higher end at $27.04 while it hit a low of $24.8. With the volume soaring to 897,381 shares, the last trade was called at $25.16. The company has a 52-week high of $54.9. The company has a market cap of $1,257 million and there are 49,971,008 shares in outstanding. The 52-week low of the share price is $15.8201.
Alder Biopharmaceuticals Inc. has lost 12.61% in the last five trading days and dropped 10.01% in the last 4 weeks. Alder Biopharmaceuticals Inc. is up 36.44% in the last 3-month period. Year-to-Date the stock performance stands at -23.83%.
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Companys pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Companys monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushings disease.